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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To evaluate in adult participants undergoing all types of surgery, the effects of pre-emptive and preventive non-steroidal anti-inflam-
matory drugs (NSAIDs) compared with post-incision NSAIDs for reducing postoperative pain and opioid consumption.
B A C K G R O U N D
This protocol contains text from a previous Cochrane protocol
(Doleman 2017a).
Description of the condition
Postoperative pain is a common consequence of surgery that af-
fects around 80% of patients. The severity of postoperative pain is
variable, with 18% of patients suffering extreme pain (Apfelbaum
2003). Pain can have deleterious effects during the postopera-
tive period, including patient dissatisfaction (Myles 2000), inter-
ference with daily activities (Strassels 2002), pulmonary compli-
cations (Desai 1999), increases in the stress response to surgery
(Desborough 2000), and an increased risk of chronic postsurgi-
cal pain (Kehlet 2006). Risk factors for severe postoperative pain
include the presence of pre-operative pain, pre-operative anxiety
and the type of surgery (Ip 2009). Intravenous opioids are com-
monly used to treat pain in the postoperative period (Benhamou
2008), however their use is associated with many side effects such
as vomiting, pruritus (itching), sedation (drowsiness) and patient
concerns over addiction (Apfelbaum 2003). Therefore, alternative
strategies to manage both postoperative pain and reduce postop-
erative opioid consumption may have important benefits for pa-
tients undergoing surgery (Zhao 2004).
Description of the intervention
Non-steroidal anti-inflammatory drugs (NSAIDs) are a com-
monly used analgesic during the peri-operative period. The mech-
anism of action of NSAIDs involves inhibition of cyclooxygenase
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(COX) enzymes, which are involved in the formation of hyper-
algesic compounds called prostaglandins (Burian 2005). NSAIDs
are effective in reducing postoperative pain, even when added to
standard regimens including paracetamol (Ong 2010). Adverse
events around the peri-operative period include possible increases
in bleeding (Warltier 2003), and acute kidney injury and gastroin-
testinal ulceration (Gilron 2003). However, newer COX-2 spe-
cific agents that do not target gastrointestinal COX-1 may offer
lower incidences of gastrointestinal ulceration compared with tra-
ditional NSAIDs (Jüni 2002), although studies have suggested an
increased risk of cardiac events in high-risk patients (Nussmeier
2005).
Pre-emptive analgesia involves the initiation of an analgesic agent
(painkiller) prior to surgical incision (before the surgeon cuts the
skin). It is thought that by initiating analgesic interventions before
surgical injury, the analgesic can provide reductions in intra-oper-
ative nociception to the central nervous system and therefore pro-
vide superior pain relief compared with the same analgesic given
post-incision (after the surgeon has cut the skin) (Kissin 2000).
Preventive analgesia extends this definition to include increasing
the intensity and duration of pre-emptive analgesic interventions
until final wound healing (Dahl 2011). The first review to examine
the clinical effects of pre-emptive analgesia showed pre-emptive
NSAIDs were ineffective in reducing pain scores or analgesic con-
sumption in most of the included trials when compared to post-
incision NSAIDs (Møiniche 2002). A second review, published a
few years later, demonstrated a lower analgesic consumption and
delayed time to first analgesic request with pre-emptive NSAIDs
(Ong 2005). However, these reviews are now outdated and im-
portantly, did not evaluate reductions in opioid side effects (from
reduced postoperative consumption) and potential intervention
adverse events.
How the intervention might work
Surgical incision promotes changes in both the central and pe-
ripheral nervous system, called sensitization. Such sensitization
can cause biochemical changes whichmanifest as hyperalgesia (the
same pain stimulus causing increased pain), and allodynia (normal
sensations causing pain). It is thought that by initiating analgesia
before surgical incision, both peripheral and central sensitization
can be reduced, resulting in reductions in intra-operative nocicep-
tion, and later, both acute and chronic postoperative pain. Pre-
ventive analgesia extends this reduction in sensitization to include
the postoperative period. This enhanced definition came from an
increased understanding of the development of persistent post-
surgical pain, which is associated with postoperative sensitization,
which may only be reduced by continuing analgesia longer into
the postoperative period (Dahl 2011). As opioids are commonly
used to treat pain postoperatively (Benhamou 2008), any reduc-
tions in opioid use may also result in a reduction in opioid adverse
events (Doleman 2015b; Zhao 2004), and improve the patient
experience.
Why it is important to do this review
Due to both its common occurrence (Apfelbaum 2003), and po-
tential deleterious effects during the postoperative period, reduc-
ing postoperative pain is an important clinical issue. A simple
change in clinical practice, such as changing the timing of ad-
ministration of analgesics, could have important implications for
postoperative pain management. Moreover, such a change is cost-
neutral and therefore may benefit both anaesthetists in low-in-
come countries and those working within healthcare systems with
finite resources (such as the National Health Service (NHS) in the
United Kingdom). A previous review has highlighted a potential
effect of pre-emptive analgesia (Ong 2005), although most of the
data were published over a decade ago, which mandates an up-
dated review of the evidence.
O B J E C T I V E S
To evaluate in adult participants undergoing all types of surgery,
the effects of pre-emptive and preventive non-steroidal anti-
inflammatory drugs (NSAIDs) compared with post-incision
NSAIDs for reducing postoperative pain and opioid consump-
tion.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include parallel group, randomized controlled trials
(RCTs) only. We will consider studies that did not use a double
dummy placebo (for example, intervention group receives active
drug before incision and placebo after incision; control group re-
ceives placebo before incision and active drug after incision). We
will exclude studies that include paediatric participants and phar-
macokinetic studies not reporting any clinical outcomes.
Types of participants
Adult patients (18 years and above) undergoing any type of surgery.
We will not include studies that include both adult and paediatric
participants.
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Types of interventions
We will compare both pre-emptive non-steroidal anti-inflam-
matory drugs (NSAIDs) and preventive NSAIDs (intervention
groups) with post-incision NSAIDs (control group). We define:
1. pre-emptive NSAIDs as NSAIDs initiated before incision
but not continued postoperatively;
2. preventive NSAIDs as NSAIDs initiated before surgical
incision and continued postoperatively; and
3. post-incision NSAIDs as the same analgesic intervention
initiated after surgical incision, whether single dose (as
comparator with pre-emptive analgesia) or continued
postoperatively (as comparator with preventive analgesia)
(control group).
We will only compare interventions if identical analgesics with
identical dosages are used. In addition, we will only include stud-
ies if concurrent use of other multimodal analgesic agents dur-
ing the peri-operative period is identical, in order to avoid con-
founding. If the studies report multiple intervention subgroups
that have comparable control groups (identical interventions), we
will combine these into one group using recommended methods
(Higgins 2011a). We will include all types of NSAIDs and COX-
2 inhibitors, at any dose, via any route of administration (oral and
parenteral) and all types of regimen (pre-emptive or preventive) in
the analysis.
Types of outcome measures
Primary outcomes
1. Early acute postoperative pain (measured within six hours
postoperatively using a validated pain scale; converted to a 0 to
10 scale where a 0 to 100 scale is used; and where multiple time
points are reported, we will include the earliest time point
reported).
2. Adverse events (re-operation for major bleeding within 30
days (yes/no)); acute kidney injury within 48 hours (defined
using published criteria (Mehta 2007) (yes/no)); gastrointestinal
ulceration or bleeding requiring endoscopy within 30 days (yes/
no); myocardial infarction within 30 days (defined as two of
three of the following: chest pain, electrocardiogram (ECG)
changes indicating ischaemia, or > 20% rise in high sensitivity
troponin (yes/no)). We will report these adverse events separately.
Secondary outcomes
1. Nausea and vomiting (self-reported by the patient or
requirement for anti-emetic; we will report nausea and vomiting
both separately and aggregated (yes/no)).
2. Late acute postoperative pain (measured at 24 to 48 hours
postoperatively using a validated pain scale; converted to a 0 to
10 scale where a 0 to 100 scale is used; and where multiple time
points are reported, we will include the earliest time point
reported).
3. 24-hour morphine consumption (mg) (if alternative
opioids are used, we will convert these to morphine-equivalents
using standard conversion factors (Doleman [in press])).
4. Time to first analgesic request (minutes).
5. Pruritus (self-reported by the patient (yes/no)).
6. Sedation (measured on a continuous scale such as the
Ramsay Sedation Scale 0 to 6 with sedation defined as 3 or more
(yes/no)).
7. Patient satisfaction (self-reported by the patient within 24
hours; converted to a 0 to 10 scale where a 0 to 100 scale is used).
8. Chronic pain (yes/no, measured three to six months
postoperatively using a validated scale, such as the Visual
Analogue Scale or the McGill Pain Questionnaire; we will
include the earliest time point closest to three months). We will
report this outcome as a separate dichotomous and continuous
outcome.
9. Time to first bowel movement (hours).
For the secondary outcomes where time points are not specified,
we will use the end point closest to two hours (one to six hours)
to assess immediate short-term effects, and the end point closest
to 24 hours (six to 48 hours) to assess longer-term effects. We
will consider a reduction in pain score of 1.5 (on a 0 to 10 scale)
(Gallagher 2001; Myles 2017), a reduction in the time to first
analgesic request of one hour, a time to first bowel movement of 12
hours and a 10mg reduction inmorphine consumption (Doleman
2015a), as clinically significant. Outcomes will not form part of
the study eligibility assessment, and so we will include studies that
meet the participant, intervention and comparison criteria in the
review even if they report no relevant outcomes.
Search methods for identification of studies
Electronic searches
We will identify RCTs through literature searching designed to
identify relevant trials as outlined in Chapter 6.4 of the Cochrane
Handbook of Systematic reviews of Interventions (Lefebvre 2011).
We will not apply restrictions to language or publication status.
We will search the following databases for relevant trials.
1. Cochrane Central Register of Controlled Trials
(CENTRAL, latest Issue) in the Cochrane Library.
2. MEDLINE (Ovid SP, 1946 onwards).
3. Embase (Ovid SP, 1974 onwards).
4. CINAHL (1982 onwards).
5. AMED (1985 onwards).
We developed a draft search strategy for MEDLINE (Appendix
1). We will used this as the basis for the search strategies in the
other databases listed.
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We will scan the following trials registries for ongoing and unpub-
lished trials.
1. World Health Organization International Clinical Trials
Registry Platform (www.who.int/ictrp/en);
2. ClinicalTrials.gov (clinicaltrials.gov).
Searching other resources
We will conduct a search of the OpenSIGLE database to identify
grey literature sources.We will scan the reference lists and citations
of included trials and any relevant systematic reviews identified
for further references to additional trials. When necessary, we will
contact trial authors for additional information. In addition, we
will search the following conference proceedings to identify further
unpublished studies (all years considered).
1. World Congress on Pain (International Association for the
Study of Pain).
2. Anaesthetic Research Society Meetings.
3. Association of Anaesthetists of Great Britain and Ireland
Winter Symposium and Annual Congress.
4. American Society of Anesthesiologists Annual Meeting.
5. European Society of Anaesthesiologists Euroanaesthesia
Conference.
Data collection and analysis
Selection of studies
We will use two review authors (BD and JPW) to independently
screen the identified studies using the inclusion criteria to assess
eligibility. BD and JPWwill resolve any disagreements by consen-
sus. If disagreement still exists following discussion, we will con-
sult a third review author (JLB). BD and JPW will use the infor-
mation from the retrieved reports to help identify any duplicate
publications, such as author name, study centre, type and dose
of interventions used and study dates. We will link any duplicate
publications. We will input details of all potentially eligible studies
into PubMed to identify any retracted publications and we will
exclude these (Eisenach 2009).
Data extraction and management
We will extract data onto an electronic database using standard-
ized data extraction forms (Appendix 2). We will perform this
independently using two review authors (BD and TH), and will
resolve any disagreements by consensus. If disagreement still ex-
ists, we will consult a third review author (JPW). We will perform
the analysis using one review author (BD). We will translate non-
English language studies and extract data following translation.
If data are not contained within the original research report, we
will contact the corresponding author, irrespective of the age of
publication. We will extract the following information.
1. Bibliographic data, including date of completion/
publication.
2. Country.
3. Publication status.
4. Source of funding.
5. Trial design, e.g. parallel.
6. Study setting.
7. Number of participants randomized to each trial arm and
number included in final analysis.
8. Eligibility criteria and key baseline participant data,
including sex and age.
9. Details of treatment regimen received by each group.
10. Details of any co-interventions.
11. Primary and secondary outcome(s) (with definitions and,
where applicable, time points).
12. Outcome data for primary and secondary outcomes (by
group).
13. Duration of follow-up.
14. Number of withdrawals (by group) and number of
withdrawals (by group) due to adverse events.
15. Adverse events.
Assessment of risk of bias in included studies
We will assess risk of bias in the included studies using the
Cochrane tool for assessing risk of bias (Higgins 2011b). Two re-
view authors (BD and JPW) will independently undertake assess-
ment of risk of bias and reach agreement by consensus. We will
assess risk of bias in the domains of sequence generation, alloca-
tion concealment, blinding of participants, study personnel and
outcome assessors, incomplete outcome data, selective outcome
reporting and other sources of bias. We will assess each domain
as low-, unclear- or high-risk of bias (Higgins 2011b). We will
present the results in both a ’Risk of bias’ summary and a ’Risk of
bias’ graph. We will interpret risk of bias across studies by reduc-
ing the quality of evidence if there is potential risk of bias in the
studies included in each analysis.
Measures of treatment effect
We will present dichotomous outcomes as risk ratios (RRs). For
continuous outcomes, we will present these as mean differences
(MDs), or if non-comparable scales are used across studies but still
presented as continuous data, we will present these as standardized
mean differences (SMDs). We will present the outcomes of time
to first analgesic and time to first bowel movement as hazard ratios
(HRs) where reported. If HRs are not reported, we attempt to cal-
culate these from reported data using published methods (Tierney
2007). We will present the precision of effect estimates using 95%
confidence intervals (CIs).
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Unit of analysis issues
As we will include parallel-group RCTs only; unit of analysis issues
are not expected for the main analysis (Higgins 2011c). For the
main results, we will combine different dose subgroups into one
treatment group, as suggested in the Cochrane Handbook for Sys-
tematic Reviews of Interventions (Higgins 2011a). If it is not possible
to combine groups (for example, for continuous outcomes where
the combined standard deviation (SD) cannot be estimated), we
will treat these as separate studies and distribute the control group
participants between these treatment groups to avoid analysing
them twice (Higgins 2011c).
Dealing with missing data
We will contact corresponding authors for any data missing from
the original publication, irrespective of publication date. If we do
not receive a response, we will extract data from published graphs.
If SDs are not reported, we will attempt to calculate these from
other reported statistics. If this is not possible, we will instead
discuss these in the narrative synthesis.
Assessment of heterogeneity
We will assess clinical heterogeneity by examining study charac-
teristics, such as the type of population, type of surgery and inter-
vention used. We will assess statistical heterogeneity using the I2
statistic. We will use the following recommended cut-off values in
the interpretation of the I2 statistic (Deeks 2011).
1. > 50% may represent moderate heterogeneity.
2. > 85% considerable heterogeneity.
In addition to the cut-off values, we will examine the direction of
the effect in the individual studies. For clinically meaningful mag-
nitudes of the pooled effect, we will explore heterogeneity using
meta-regression when the criteria set out in Subgroup analysis and
investigation of heterogeneity section are fulfilled.
Assessment of reporting biases
If we include 10 ormore studies in themeta-analysis, we will assess
publication bias graphically using funnel plots and quantitatively
using Egger’s linear regression test (Egger 1997). Due to the low
power of this test, we will regard P < 0.1 as evidence of imprecise
study effects and possible publication bias.
Data synthesis
We will use Review Manager 5 to aggregate study data (Review
Manager 2014). We will conduct separate analyses for pre-emp-
tive and preventive interventions. We will aggregate data using the
adapted DerSimonian and Laird random-effects model (for con-
tinuous and categorical outcomes), as currently available inReview
Manager 5. This is because we expect the treatment effect to vary
with respect to the different populations within each study, and
therefore there is no single underlying effect to estimate, making
the random-effects model more appropriate. We will aggregate re-
ported log hazard ratios and their associated standard errors using
the generic inverse variance method. If we are unable to synthesize
results, we will discuss them in a narrative synthesis.
Subgroup analysis and investigation of heterogeneity
If there are sufficient included studies, we will consider conduct-
ing two separate subgroup analyses for the type of NSAIDs (non-
COX-2 versus COX-2 inhibitor) and trials with different baseline
pain levels (mean pain scores in the control group of < 3 (mild),
3 to 6 (moderate) and > 6 (severe)) (Moore 2013). If we include
10 studies or more in a meta-analysis and the included studies
have a sufficient number of events, we will explore reasons for het-
erogeneity by performing a restricted maximum likelihood, ran-
dom-effects meta-regression using the covariates: type and dose
of NSAIDs; type of anaesthesia; and type of surgery (Thompson
2002). For dummy variables, we will use the least effective sub-
group as the reference category. We will present the R2 analogue
with a corresponding P value for each covariate. We will use the
Knapp-Hartungmethod to calculate P values (as thismethodmore
appropriately uses the t-distribution for the between-study vari-
ance). We will perform this analysis using the software STATA
Version 15 (Stata 2017). If there is a low number of studies, or
events, or both, we will only perform traditional subgroup analy-
sis, and report the P value for subgroup differences.
Sensitivity analysis
We will perform a sensitivity analysis by restricting the analysis to
studies at low-risk of bias (defined as low-risk for randomization
and allocation concealment). As we will judge studies that did not
use a double dummy design at high-risk of bias for blinding, we
will assess the impact of excluding these from the analysis. We
will also perform a further sensitivity analysis by excluding studies
where SDs were estimated. As a further sensitivity analysis, we
will analyse only the participants whose outcomes were measured
(available case analysis) to assess the robustness of the findings.
’Summary of findings’ table and GRADE
We will present outcomes in a ’Summary of findings’ table. We
will produce two ’Summary of findings’ tables, one for each com-
parison.
1. Pre-emptive NSAIDs versus single dose post-incision
NSAIDs.
2. Preventive NSAIDs versus continuous post-incision
NSAIDs.
The outcomes for each comparison will include: early acute post-
operative pain; adverse events: nausea and vomiting; late acute
postoperative pain; 24-hour morphine consumption; time to first
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analgesic request; and chronic pain. We will present these using
the GRADE approach (Schünemann 2011). We will downgrade
the quality of evidence from high-quality to moderate-, low- or
very low-quality. Downgrading will be undertaken independently
by two review authors (BD and JPW) and agreement reached by
consensus. Characteristics of the evidence that will cause down-
grading include:
1. limitations in the design and implementation of available
studies, suggesting a high likelihood of bias (for example, studies
not using a double dummy placebo design);
2. indirectness of evidence (indirect population, intervention,
control or outcomes);
3. inconsistency of results;
4. imprecision of results (wide confidence intervals);
5. evidence of publication bias from asymmetry of the funnel
plot.
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A P P E N D I C E S
Appendix 1. MEDLINE search strategy
1. exp Anti-Inflammatory Agents, Non-Steroidal/
2. (NSAID* or non-steroidal anti-inflammatory drug* or cyclooxygenase enzyme* or cox or ibuprofen or ketoprofen or diclofenac or
indomethacin or ketorolac or naproxen or celecoxib or parecoxib or valdecoxib).tw
3. 1 or 2
4. exp Pain, Postoperative/
5. ((postoperati* or post-operati*) adj6 (pain* or recover*)).ti,ab
6. 4 or 5
7. 3 and 6
8. ((randomized controlled trial or controlled clinical trial).pt. or randomi?ed.ab. or placebo.ab. or clinical trials as topic.sh. or ran-
domly.ab. or trial.ti.) not (exp animals/ not humans.sh.)
9. 7 and 8
10. (exp child/ or exp infant/) not exp adult/
11. 9 not 10
12. expPreanestheticMedication/ or (pre-emptive or preemptive or preventive or preoperati* or pre-operat* or preincision or pre-incision
or perioperati* or peri-operati* or intraoperati* or intra-operati* or prophylactic* or ((before or prior) adj3 (surg* or operat*))).ti,ab
13. 11 and 12
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Appendix 2. Data Extraction Form
Data collection form
Review title or ID
Study ID (surname of first author and year first full report of study was published e.g. Smith 2001)
Report IDs of other reports of this study (e.g. duplicate publications, follow-up studies)
Notes:
1. General Information
Date form completed (dd/mm/yyyy)
Name/ID of person extracting data
Report title
(title of paper/ abstract/ report that data are extracted from)
Report ID
(ID for this paper/ abstract/ report)
Reference details
Report author contact details
Publication type
(e.g. full report, abstract, letter)
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(Continued)
Study funding sources
(including role of funders)
Possible conflicts of interest
(for study authors)
Notes:
2. Study Eligibility
Study Charac-
teristics
Eligibility criteria
(Insert eligibility criteria for each
characteristic as defined in the pro-
tocol)
Yes No Unclear Location in text
(pg & /fig/table)
Type of study Randomized Controlled Trial
Controlled Clinical Trial
(quasi-randomized trial)
Participants
Types of inter-
vention
Types of out-
come measures
INCLUDE EXCLUDE
Reason for ex-
clusion
Notes:
DO NOT PROCEED IF STUDY EXCLUDED FROM REVIEW
3. Population and setting
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Description
Include comparative information for
each group (i.e. intervention and con-
trols) if available
Location in text
(pg & ¶/fig/table)
Population description
(from which study participants
are drawn)
Setting
(including location and social
context)
Inclusion criteria
Exclusion criteria
Method/s of recruitment of
participants
Informed consent obtained Yes No Unclear
Notes:
4. Methods
Descriptions as stated in report/
paper
Location in text
(pg & ¶/fig/table)
Aim of study
Design (e.g. parallel, cross-over,
cluster)
Unit of allocation
(by individuals, cluster/ groups or
body parts)
Start date
End date
Total study duration
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(Continued)
Ethical approval needed/ ob-
tained for study
Yes No Unclear
Notes:
5. Risk of bias assessment
See Chapter 8 of the Cochrane Handbook
Domain Risk of bias Support for judgement Location in text
(pg & ¶/fig/table)
Low-risk High-risk Unclear
Random sequence
generation
(selection bias)
Allocation
concealment
(selection bias)
Blinding of partic-
ipants and person-
nel
(performance bias)
Outcome group: All/
(if required) Outcome group:
Blinding of out-
come assessment
(detection bias)
Outcome group: All/
(if required) Outcome group:
Incomplete
outcome data
(attrition bias)
Selective outcome
reporting?
(reporting bias)
Other bias
Notes:
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6. Participants
Provide overall data and, if available, comparative data for each intervention or comparison group.
Description as stated in report/paper Location in text
(pg & ¶/fig/table)
Total no. randomized
(or total pop. at start of study for NRCTs)
Clusters
(if applicable, no., type, no. people per cluster)
Baseline imbalances
Withdrawals and exclusions
(if not provided below by outcome)
Age
Sex
Race/ethnicity
Severity of illness
Comorbidities
Other treatment received (additional to
study intervention)
Other relevant sociodemographics
Subgroups measured
Subgroups reported
Notes:
7. Intervention groups
Copy and paste table for each intervention and comparison group
Intervention group 1
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Description as stated in report/paper Location in text
(pg & ¶/fig/table)
Group name
No. randomized to group
(specify whether no. people or clusters)
Theoretical basis (include key references)
Description (include sufficient detail for
replication, e.g. content, dose, components)
Duration of treatment period
Timing (e.g. frequency, duration of each
episode)
Delivery (e.g. mechanism, medium, inten-
sity, fidelity)
Providers
(e.g. no., profession, training, ethnicity etc. if
relevant)
Co-interventions
Economic variables
(i.e. intervention cost, changes in other costs
as result of intervention)
Resource requirements to replicate inter-
vention
(e.g. staff numbers, cold chain, equipment)
Notes:
8. Outcomes
Copy and paste table for each outcome.
Outcome 1
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Description as stated in report/
paper
Location in text
(pg & ¶/fig/table)
Outcome name
Time points measured
Time points reported
Outcome definition (with di-
agnostic criteria if relevant)
Person measuring/reporting
Unit of measurement
(if relevant)
Scales: upper and lower lim-
its (indicate whether high or low
score is good)
Is outcome/tool validated? Yes No Unclear
Imputation of missing data
(e.g. assumptions made for ITT
analysis)
Assumed risk estimate
(e.g. baseline or population risk
noted in Background)
Power
Notes:
9. Results
Copy and paste the appropriate table for each outcome, including additional tables for each time point and subgroup as required.
Dichotomous outcome
Description as stated in report/paper Location in text
(pg & ¶/fig/table)
Comparison
Outcome
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(Continued)
Subgroup
Time point
(specify whether
from start or end
of intervention)
Results Intervention Comparison
No. events No. participants No. events No. participants
No. miss-
ing participants
and reasons
No. par-
ticipants moved
from
other group and
reasons
Any other re-
sults reported
Unit of analy-
sis (by individu-
als, cluster/groups
or body parts)
Sta-
tistical methods
used and appro-
priateness
of these meth-
ods (e.g. adjust-
ment for correla-
tion)
Reanalysis re-
quired? (specify)
Yes No Unclear
Reanalysis pos-
sible?
Yes No Unclear
Reanalysed re-
sults
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(Continued)
Notes:
Continuous outcome
Description as stated in report/paper Location in text
(pg & ¶/fig/table)
Comparison
Outcome
Subgroup
Time point
(specify whether from
start or end of inter-
vention)
Post-interven-
tion or change from
baseline?
Results Intervention Comparison
Mean SD
(or other
variance)
No.
participants
Mean SD (or
other vari-
ance)
No. partici-
pants
No. missing partic-
ipants and reasons
No. participants
moved from other
group and reasons
Any other results
reported
Unit of analysis
(individuals, cluster/
groups or body parts)
Statistical methods
used and appro-
priateness of these
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(Continued)
methods (e.g. adjust-
ment for correlation)
Reanalysis
required? (specify)
Yes No Unclear
Reanalysis
possible?
Yes No Unclear
Reanalysed results
Notes:
Other outcome
Description as stated in report/paper Location in text
(pg & ¶/fig/table)
Comparison
Outcome
Subgroup
Time point
(specify whether
from start or end
of intervention)
Results Intervention re-
sult
SD (or other vari-
ance)
Control result SD (or other variance)
Overall results SE (or other variance)
No.
participants
Intervention Control
No. miss-
ing participants
and reasons
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(Continued)
No. par-
ticipants moved
from
other group and
reasons
Any other re-
sults reported
Unit of analy-
sis (by individu-
als, cluster/groups
or body parts)
Sta-
tistical methods
used and ap-
propriateness of
these methods
Reanalysis re-
quired? (specify)
Yes No Unclear
Reanalysis pos-
sible?
Yes No Unclear
Reanalysed re-
sults
Notes:
10. Applicability
Have important populations been ex-
cluded from the study? (consider disadvan-
taged populations, and possible differences in
the intervention effect)
Yes No Unclear
Is the intervention likely to be aimed at
disadvantaged groups? (e.g .lower socioeco-
nomic groups)
Yes No Unclear
Does the study directly address the re-
view question?
(any issues of partial or indirect applicability)
Yes No Unclear
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(Continued)
Notes:
11. Other information
Description as stated in report/paper Location in text
(pg & ¶/fig/table)
Key conclusions of study authors
References to other relevant studies
Correspondence required for further
study information (from whom, what and
when)
Notes:
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